Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Positron emission tomography (PET): expanding the horizons of oncology drug development.

Hammond LA, Denis L, Salman U, Jerabek P, Thomas CR Jr, Kuhn JG.

Invest New Drugs. 2003 Aug;21(3):309-40. Review.

PMID:
14578681
2.

The role of positron emission tomography in pharmacokinetic analysis.

Fischman AJ, Alpert NM, Babich JW, Rubin RH.

Drug Metab Rev. 1997 Nov;29(4):923-56. Review.

PMID:
9421680
3.

Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials.

Osman S, Luthra SK, Brady F, Hume SP, Brown G, Harte RJ, Matthews JC, Denny WA, Baguley BC, Jones T, Price PM.

Cancer Res. 1997 Jun 1;57(11):2172-80.

4.

PET for in vivo pharmacokinetic and pharmacodynamic measurements.

Gupta N, Price PM, Aboagye EO.

Eur J Cancer. 2002 Nov;38(16):2094-107. Review.

PMID:
12387835
5.

Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.

Osman S, Rowlinson-Busza G, Luthra SK, Aboagye EO, Brown GD, Brady F, Myers R, Gamage SA, Denny WA, Baguley BC, Price PM.

Cancer Res. 2001 Apr 1;61(7):2935-44.

6.

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.

Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PM, Price PM, Zweit J; Cancer Research UK Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee.

J Natl Cancer Inst. 2006 May 3;98(9):580-98. Review.

PMID:
16670384
7.

What does positron emission tomography offer oncology?

Anderson H, Price P.

Eur J Cancer. 2000 Oct;36(16):2028-35. Review.

PMID:
11044638
8.

Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action.

Fischman AJ, Alpert NM, Rubin RH.

Clin Pharmacokinet. 2002;41(8):581-602. Review.

PMID:
12102642
9.

Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET.

Brady F, Luthra SK, Brown GD, Osman S, Aboagye E, Saleem A, Price PM.

Curr Pharm Des. 2001 Dec;7(18):1863-92. Review.

PMID:
11772355
10.

The use of imaging in preclinical drug development.

Vanderheyden JL.

Q J Nucl Med Mol Imaging. 2009 Aug;53(4):374-81.

11.

Trends in nucleoside tracers for PET imaging of cell proliferation.

Toyohara J, Fujibayashi Y.

Nucl Med Biol. 2003 Oct;30(7):681-5. Review. No abstract available.

PMID:
14499325
12.

Autoradiography with positron emitting isotopes in positron emission tomography tracer discovery.

Bergström M, Awad R, Estrada S, Mälman J, Lu L, Lendvai G, Bergström-Pettermann E, Långström B.

Mol Imaging Biol. 2003 Nov-Dec;5(6):390-6.

PMID:
14667493
14.

Fundamentals of positron emission tomography and applications in preclinical drug development.

Cherry SR.

J Clin Pharmacol. 2001 May;41(5):482-91. Review.

PMID:
11361044
15.

Realizing the full potential of PET for measuring the biodistribution of novel anticancer agents.

Jones T, Price P, Tavitian B.

J Nucl Med. 2011 Sep;52(9):1500. doi: 10.2967/jnumed.111.094920. Epub 2011 Aug 8. No abstract available.

16.

The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography.

Collingridge DR, Carroll VA, Glaser M, Aboagye EO, Osman S, Hutchinson OC, Barthel H, Luthra SK, Brady F, Bicknell R, Price P, Harris AL.

Cancer Res. 2002 Oct 15;62(20):5912-9.

17.

Clinical molecular imaging with positron emission tomography.

Saleem A, Charnley N, Price P.

Eur J Cancer. 2006 Aug;42(12):1720-7. Epub 2006 Jun 22. Review.

PMID:
16797972
18.

Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes.

Saleem A, Aboagye EO, Matthews JC, Price PM.

Cancer Chemother Pharmacol. 2008 Apr;61(5):865-73. Epub 2007 Jul 18.

PMID:
17639391
19.
20.

Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.

England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, Liu G, McNeel DG, Barnhart TE, Cai W.

J Nucl Med. 2017 Jan;58(1):162-168. doi: 10.2967/jnumed.116.177857. Epub 2016 Aug 4.

Supplemental Content

Support Center